Physician profile
Travis Lipscomb
NPI 1639798903
$3,275.99
in general payments reported to CMS, 2019-2025
29 companies · $823 in 2025
The $823 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $24.72 · 2021: $380 · 2022: $34.65 · 2023: $574 · 2024: $1,440 · 2025: $823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,837.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,837.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $448.92 | 2023-2025 | |
| Amgen INC. | $390.89 | 2023-2025 | Evenity, Repatha, Otezla |
| Astrazeneca Pharmaceuticals Lp | $349.72 | 2021-2025 | Airsupra, Farxiga |
| Axsome Therapeutics, INC. | $304.05 | 2023-2025 | Auvelity |
| Novo Nordisk INC | $230.68 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $191.71 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.74 | 2021-2024 | |
| Lilly USA, LLC | $134.51 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $123.01 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $115.67 | 2024 | Trintellix |
| Corcept Therapeutics | $77.89 | 2025 | Korlym |
| Otsuka America Pharmaceutical, INC. | $77.47 | 2023-2025 | Rexulti |
| Insightec,INC | $77.26 | 2023 | Exablate |
| Supernus Pharmaceuticals, INC. | $57.10 | 2024 | Qelbree |
| Insulet Corporation | $56.86 | 2020-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $54.41 | 2024-2025 | Acthar |
| Merck Sharp & Dohme LLC | $52.11 | 2021-2025 | Capvaxive, Gardasil 9, Gardasil |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $43.61 | 2023-2024 | Caplyta |
| Dexcom, INC. | $40.51 | 2022-2024 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $37.99 | 2024 | Veozah |
| Philips North America LLC | $36.19 | 2024 | (Ck6) Holter |
| Edwards Lifesciences Corporation | $35.83 | 2023-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Medtronic, INC. | $32.76 | 2021-2025 | Inceptiv |
| Daiichi Sankyo INC. | $29.16 | 2024 | Injectafer |
| Harmony Biosciences LLC | $24.86 | 2025 | |
| Mannkind Corporation | $24.45 | 2024 | |
| Exact Sciences Corporation | $23.59 | 2025 | The Cologuard Plus Collection Kit |
| Amneal Pharmaceuticals LLC | $16.23 | 2024 | Unithroid |
| Watermark Medical, INC. | $14.81 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Lipscomb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.